Key result
Speed modulation in continuous-flow VADs enhances arterial pulsatility in animal and computational models via flow-time integral differences, but shows limited clinical effectiveness.
Why the study?
Continuous-flow ventricular assist devices (CF-VADs) attenuate arterial pulsatility, potentially predisposing patients to endothelial dysfunction and gastrointestinal bleeding. Although speed modulation has been proposed to reconstruct arterial pulsatility, its effectiveness and underlying mechanisms remain incompletely understood.
Does speed modulation in continuous-flow ventricular assist devices improve arterial pulsatility and vascular function in preclinical models and patients?
Does speed modulation in continuous-flow ventricular assist devices improve arterial pulsatility and vascular function in preclinical models and patients?
While CF-VAD speed modulation enhances arterial pulsatility in animal and computational models via differences in flow-time integrals, current clinical algorithms have not consistently improved pulsatility or vascular function in patients.
Answers are grounded in this paper and cite their sources.
Speed modulation for CF-VAD pulsatility lacks clinical confirmation; leaves open optimal parameters and outcomes in prospective trials.
BACKGROUND: Continuous-flow ventricular assist devices (CF-VADs) attenuate arterial pulsatility, potentially predisposing patients to complications such as endothelial dysfunction and gastrointestinal bleeding. Speed modulation has been proposed to reconstruct arterial pulsatility, but its effectiveness and underlying mechanisms remain incompletely understood. METHODS: A structured narrative review was conducted using studies identified from PubMed, Scopus, and Web of Science through June 2026. Evidence from animal experiments, mock circulatory loop studies, lumped-parameter models, and clinical investigations was synthesized. A Windkessel-based framework was used to interpret the effects of modulation parameters on arterial pulsatility. RESULTS: Animal and computational studies generally demonstrate that speed modulation can enhance arterial pulsatility, with the enhancement depending on factors such as modulation amplitude, waveform, frequency (i.e., the duration of high- and low-speed phases) and phase relationship. Windkessel-based analysis further indicates that pulsatility enhancement is governed by differences in flow-time integrals between modulation phases, providing a mechanistic explanation for the observed effects of modulation parameters. However, clinically implemented speed modulation algorithms have not consistently produced significant improvements in arterial pulsatility or vascular function. CONCLUSIONS: Speed modulation can enhance arterial pulsatility under animal and computational conditions, but its clinical effectiveness remains limited. This discrepancy may reflect constraints on modulation amplitude and duration imposed by hemocompatibility, ventricular safety, and device reliability. Future research should integrate multiscale hemodynamic and hemocompatibility assessments, long-term animal and clinical validation, and advanced device designs and control strategies.
No takes yet. Share an insight, caveat, or question.
Fang et al. (2026) conducted a review in Heart failure supported by continuous-flow ventricular assist devices (CF-VADs). Speed modulation in continuous-flow ventricular assist devices (CF-VADs) vs. Unmodulated continuous-flow ventricular assist device operation was evaluated on Arterial pulsatility and vascular function. Speed modulation in continuous-flow VADs enhances arterial pulsatility in animal and computational models via flow-time integral differences, but shows limited clinical effectiveness.
Synapse has enriched 10 related papers. Consider them for comparative context: